Global Distribution Agreements, New Clinical Study Results, FDA Announcements, and Earnings Schedules - Research Report on Life Technologies, GW, Novartis, Salix, and Mallinckrodt

NEW YORK, October 10, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Life Technologies Corporation (NASDAQ: LIFE), GW Pharmaceuticals plc (NASDAQ: GWPH), Novartis AG (NYSE: NVS), Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP), and Mallinckrodt plc (NYSE: MNK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Life Technologies Corporation Research Report

On September 30, 2013, Life Technologies Corporation (Life Technologies) announced a global distribution agreement with Advanced Cell Diagnostics, Inc. (ACD) under which Life Technologies will distribute ACD's fluorescent RNAscope portfolio of probes and kits to the research market through its worldwide distribution network. "RNAscope complements our existing portfolio and solves long-standing technical hurdles researchers have encountered when studying heterogeneous samples," said Siddhartha Kadia, Ph.D., President of Life Sciences at Life Technologies. "RNAscope's ability to provide single-molecule RNA detection, while preserving tissue context makes it easy to pinpoint which biomarker is expressed in specific cells -- all at the convenience of a conventional fluorescence microscope." The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d5de_LIFE]

--

GW Pharmaceuticals plc Research Report

On October 2, 2013, GW Pharmaceuticals plc (GW) announced that data from new MS spasticity studies is being presented at the 29^th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. GW's commercial partner, Almirall S.A. (Almirall) stated that the data shows that Sativex effectiveness is maintained long term with no additional safety concerns identified in clinical practice. Dr. Tiina Rekand of the Haukeland University Hospital Bergen, Norway commented, "Sativex can improve the spasticity symptoms impairment of MS patients without affecting such issues as driving ability, cognition or mood." The Full Research Report on GW Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/26a5_GWPH]

--

Novartis AG Research Report

On October 5, 2013, Novartis AG (Novartis) announced positive results from the Phase III ASTERIA I study. The results showed that omalizumab was effective and safe in the treatment of chronic spontaneous urticaria (CSU), a chronic and debilitating form of hives. The Company informed that these results were presented for the first time at the 22nd Congress of the European Association of Dermatology and Venereology (EADV) in Istanbul, Turkey. Currently, omalizumab is not approved for the treatment of CSU. Commenting on the new results, Tim Wright, Global Head of Development at Novartis Pharmaceuticals said, "The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond to approved doses of antihistamines, the only licensed treatment option." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

--

Salix Pharmaceuticals, Ltd. Research Report

On October 1, 2013, Salix Pharmaceuticals, Ltd. (Salix) and Progenics Pharmaceuticals (Progenics) announced that the FDA will convene an Advisory Committee on March 10-11, 2014, at which time Salix's sNDA (Supplemental New Drug Application) for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, for opioid-induced constipation (OIC) in patients with chronic pain will be considered. The Companies informed that the FDA's action to convene an Advisory Committee was taken in response to the formal appeal made by Salix regarding the complete response action taken by the FDA on July 27, 2012 involving the RELISTOR sNDA for chronic pain. The FDA said that it will take action under the appeal within 30 days after receiving input from the Advisory Committee. The Full Research Report on Salix Pharmaceuticals, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/04fa_SLXP]

--

Mallinckrodt plc Research Report

On October 7, 2013, Mallinckrodt plc (Mallinckrodt) announced that it will report its Q4 FY 2013 results on November 7, 2013. The Company will also hold a conference call for investors at 8:30 a.m. US EDT on the same day to discuss the results. The call can be accessed at the Company's website or via telephone. Also, an archived version of the call will be available at its website until 12:59 p.m. US EDT on November 14, 2013. The Full Research Report on Mallinckrodt plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/24f6_MNK]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner